Topic: non-small cell lung cancer
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
The results of a phase 3 trial suggest dacomitinib is more effective than its aging rival.
The funding will advance Rain's hypoxia-activated prodrug in patients with non-small cell lung cancer for whom there are no treatments.
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.
The drug shrunk the tumors of most patients in the trial, raising hopes it can become a new treatment option for patients with RET-altered cancers.
Blueprint's data shows its BLU-667 caused some tumor shrinkage in 84% of patients with lung or thyroid cancer.
AstraZeneca will supply fast-growing NSCLC therapy Tagrisso for free in the study, which will see if MP0250 can restore sensitivity to AZ's drug.
AbbVie is abandoning plans to seek out an FDA quick OK for its troubled oncology drug Rova-T in third-line relapsed/refractory small cell lung cancer.
Bristol-Myers Squibb has added Yale Cancer Center to its list of participants in a cancer immunotherapy initiative.